021-51111890
购物车（0）
sales@molnova.cn
Amiselimod hydrochloride
CAS No. 942398-84-7
Amiselimod hydrochloride ( MT-1303 hydrochloride )
产品货号. M16743 CAS No. 942398-84-7
一种新型前药 S1P 受体调节剂，缺乏 S1P3 受体激动作用，可避免与芬戈莫德和其他 S1P 受体调节剂相关的心动过缓。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥437 | 有现货 |
|
| 5MG | ￥721 | 有现货 |
|
| 10MG | ￥1077 | 有现货 |
|
| 25MG | ￥1831 | 有现货 |
|
| 50MG | ￥3216 | 有现货 |
|
| 100MG | ￥4836 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Amiselimod hydrochloride
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述一种新型前药 S1P 受体调节剂，缺乏 S1P3 受体激动作用，可避免与芬戈莫德和其他 S1P 受体调节剂相关的心动过缓。
-
产品描述A novel prodrug S1P receptor modulator lacking S1P3 receptor agonism to avoid bradycardia associated with fingolimod and other S1P receptor modulators; the selectivity of the active metabolite amiselimod phosphate (Amiselimod-P) shows potent selectivity for S1P1 and high selectivity for S1P5 receptors, with minimal agonist activity for S1P4 and no distinct agonist activity for S1P2 or S1P3 receptors and approximately five-fold weaker GIRK activation than fingolimod-P; exhibits potent therapeutic efficacy with minimal cardiac effects.Multiple Sclerosis Phase 2 Clinical.
-
体外实验——
-
体内实验——
-
同义词MT-1303 hydrochloride
-
通路GPCR/G Protein
-
靶点Lysophospholipid Receptor
-
受体Lysophospholipid Receptor
-
研究领域Inflammation/Immunology
-
适应症Multiple Sclerosis
化学信息
-
CAS Number942398-84-7
-
分子量413.9026
-
分子式C19H31ClF3NO3
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 32 mg/mL
-
SMILESCCCCCCCOC1=C(C=C(C=C1)CCC(CO)(CO)N)C(F)(F)F.Cl
-
化学全称1,3-Propanediol, 2-amino-2-[2-[4-(heptyloxy)-3-(trifluoromethyl)phenyl]ethyl]-, hydrochloride (1:1)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Sugahara K, et al. Br J Pharmacol. 2017 Jan;174(1):15-27.
2. Kappos L, et al. Lancet Neurol. 2016 Oct;15(11):1148-59.
3. Harada T, et al. Br J Clin Pharmacol. 2017 May;83(5):1011-1027.
